Development of therapeutic siRNAs for pachyonychia congenita.
about
Molecular therapeutics for heritable skin diseasesProgress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promiseIn vivo imaging of human and mouse skin with a handheld dual-axis confocal fluorescence microscope.siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model.Increased interstitial pressure improves nucleic acid delivery to skin enabling a comparative analysis of constitutive promoters.Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy.Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD)PCQoL: A Quality of Life Assessment Measure for Pachyonychia Congenita.Guanidinium-rich, glycerol-derived oligocarbonates: a new class of cell-penetrating molecular transporters that complex, deliver, and release siRNANon-Invasive Intravital Imaging of siRNA-Mediated Mutant Keratin Gene Repression in Skin.Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells.Novel molecular therapies for heritable skin disordersMerging molecular imaging and RNA interference: early experience in live animalsTherapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita.Cutaneous short-interfering RNA therapy.Regulation of cytokines by small RNAs during skin inflammation.miRNAs in inflammatory skin diseases and their clinical implications.microRNAs in Psoriasis.Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model.In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation.Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy.Topical delivery of TRPsiRNA-loaded solid lipid nanoparticles confer reduced pain sensation via TRPV1 silencing, in rats.Fractional thermolysis by bipolar radiofrequency facilitates cutaneous delivery of peptide and siRNA with minor loss of barrier function.Disorders of Keratinization
P2860
Q26865551-88035CFA-D394-43C9-A629-B1B7C12F692CQ28393706-E09724B9-BDD4-4E31-ADDA-BA40A12FCC3FQ30557750-51A0DBF8-223A-44F0-A781-9CE7A8434625Q33454280-14C73CC7-F201-484D-B34C-4A88BD665B17Q33576601-E01032C4-DA01-4266-9D9A-161D2DCDB551Q34103212-5869F109-BC4E-43CD-A117-6CEFEF450E6FQ34209790-40D0D76E-92B0-41BB-986C-37EF263BE520Q34467382-C12B2956-6BB7-4B86-BD96-59797B55AA6FQ35535949-4418D230-8321-473A-8ED1-96862DE774ACQ35689975-BCE66325-50FB-4704-9176-8094323D72A7Q36170747-97AA5473-DC9F-4408-B800-376FD220CE7AQ36610899-BEEBB954-F31A-4FED-8A2F-4DD9C852FBEEQ37076203-3C23FE7D-5EBD-4DBF-92A7-1BD3DA9A018DQ37169944-C4BC1DBA-E8B1-4C93-8323-463741F37DCAQ37639312-50DC2316-574A-4154-A7E4-C6A074487952Q37769284-E339DAAD-95B8-4204-99B2-B058EFED21C7Q38365504-82E42BB3-235E-410F-A1D3-30906613FED4Q38708656-C886868C-6281-4183-A591-99AB91E11E79Q39502368-6DA0E939-6353-4998-8E48-17363B6900C5Q41865099-A5EB1EF9-3B33-4159-BCA6-41CC093453FBQ42781100-6F2DC67C-52BA-478B-B79A-5E666CE3F592Q47965414-B362BBAC-7CAA-49C9-88DA-388DD835E99CQ53393012-FCFB2703-7A3A-488F-AC28-F02B0292726DQ58859701-FC8241A7-BF20-4AB6-94AA-8F1D30EFE896
P2860
Development of therapeutic siRNAs for pachyonychia congenita.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Development of therapeutic siRNAs for pachyonychia congenita.
@en
type
label
Development of therapeutic siRNAs for pachyonychia congenita.
@en
prefLabel
Development of therapeutic siRNAs for pachyonychia congenita.
@en
P2093
P356
P1476
Development of therapeutic siRNAs for pachyonychia congenita.
@en
P2093
Devin Leake
Frances J D Smith
Jane M Sayers
Robert E Reeves
Robyn P Hickerson
Roger L Kaspar
P2888
P356
10.1038/SJ.JID.5701040
P407
P577
2007-08-30T00:00:00Z